Patents by Inventor Alexander L Weis
Alexander L Weis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6242428Abstract: The invention relates to novel nucleosides and nucleoside dimers containing an L-sugar in at least one of the nucleosides, and their pharmaceutical compositions.Type: GrantFiled: December 23, 1998Date of Patent: June 5, 2001Assignees: Unisearch Limited, Lipitek International Inc.Inventors: Alexander L Weis, Kirupathevy Pulenthiran, Annette M. Gero
-
Patent number: 6207649Abstract: The invention relates to pharmaceutical compositions of nucleoside dimers containing an L-sugar in at least one of the nucleosides.Type: GrantFiled: December 23, 1998Date of Patent: March 27, 2001Assignee: Lipitek International, Inc.Inventors: Alexander L Weis, Kirupathevy Pulenthiran
-
Patent number: 6025335Abstract: The invention relates to nucleoside dimers containing an L-sugar in at least one of the nucleosides and their pharmaceutical compositions.Type: GrantFiled: September 21, 1995Date of Patent: February 15, 2000Assignee: Lipitek International, Inc.Inventors: Alexander L. Weis, Charles T. Goodhue, Kirupathevy Pulenthiran
-
Patent number: 5939402Abstract: The invention relates to novel nucleosides and nucleoside dimers containing an L-sugar in at least one of the nucleosides, and their pharmaceutical compositions.Type: GrantFiled: March 11, 1998Date of Patent: August 17, 1999Assignee: Lipitek International, Inc.Inventors: Alexander L. Weis, Kirupathevy Pulenthiran
-
Patent number: 5885972Abstract: This invention relates to .alpha. and .beta.-L-pyranosyl nucleosides of Formula (I), wherein the nucleoside substitution on the pyranosyl carbohydrate molecule comprises a substituted or unsubstituted purine (adenine or guanine) or pyrimidine (cytosine, uracil, thymine and hypoxanthine) base. Also provided are methods to make the .alpha. and .beta.-L-pyranosyl nucleosides and methods of using such to treat cancer in a mammal.Type: GrantFiled: October 2, 1996Date of Patent: March 23, 1999Assignee: Genencor International, Inc.Inventors: Alexander L. Weis, Charles T. Goodhue
-
Patent number: 5672594Abstract: This invention relates to .alpha. and .beta.-L-erythrosyl nucleosides of the formula (I), wherein the nucleoside substitution on the erythrosyl carbohydrate molecule comprises a substituted or unsubstituted purine (adenine or guanine) or pyrimidine (cytosine, uracil, thymine and hypoxanthine) base. Also provided are methods to make the .alpha. and .beta.-L-erythrosyl nucleosides and methods of using such to treat cancer in a mammal.Type: GrantFiled: October 24, 1994Date of Patent: September 30, 1997Assignee: Genencor International, Inc.Inventors: Alexander L. Weis, Tamas Bakos, Charles T. Goodhue
-
Patent number: 5604095Abstract: The present invention provides novel bis-naphthalimides characterized by having a linker containing a heteroatom, their preparation, pharmaceutical compositions thereof, and various methods of using the bis-naphthalimides. Particularly preferred bis-naphthalimides have a linker of about 8-16 atoms where the heteroatom is oxygen, sulfur, sulfur oxide or sulfur dioxide. The bis-naphthalimides provided herein have exceptional DNA binding properties and demonstrate cytotoxicity in both in vitro and in vivo tumor models, in particular, against melanoma.Type: GrantFiled: July 22, 1994Date of Patent: February 18, 1997Assignee: Cancer Therapy & Research CenterInventors: Alexander L. Weis, Shih-Fong Chen, Peech S. Reedy, Mallaiah Mittakanti, Daniel L. Dexter
-
Patent number: 5567810Abstract: Compounds, compositions and methods for inhibiting gene expression are disclosed. The compounds comprise oligonucleotide sequences of from about 9 to about 200 bases having a diol at either or both termini. Preferred diols are polyalkyleneglycols, preferably polyethyleneglycols. Pharmaceutical compositions comprising the compounds and a physiologically acceptable carrier and methods of inhibiting gene expression in mammals comprising administering such compounds are also provided. Methods for inhibiting nuclease cleavage of compounds are also provided.Type: GrantFiled: May 31, 1995Date of Patent: October 22, 1996Assignee: Sterling Drug, Inc.Inventors: Alexander L. Weis, Fred T. Oakes, Frederick H. Hausheer, Paul F. Cavanaugh, Jr., Patricia S. Moskwa
-
Patent number: 5561042Abstract: The present invention provides novel bis-naphthalimides characterized by having a linker containing a heteroatom, their preparation, pharmaceutical compositions thereof, and various methods of using the bis-naphthalimides. Particularly preferred bis-naphthalimides have a linker of about 8-16 atoms where the heteroatom is oxygen, sulfur, sulfur oxide or sulfur dioxide. The bis-naphthalimides provided herein have exceptional DNA binding properties and demonstrate cytotoxicity in both in vitro and in vivo tumor models, in particular, against melanoma. Also provided a novel mono-naphthalimides linked to a DNA alkylating agent. These agents are shown to have conformational effects on double stranded DNA and to form covalent adducts after an extended incubation period.Type: GrantFiled: January 30, 1995Date of Patent: October 1, 1996Assignee: Cancer Therapy and Research CenterInventors: Alexander L. Weis, Shih-Fong Chen, Peech S. Reddy, Mallaiah Mittakanti, Daniel L. Dexter, Jan M. Woynarowski
-
Patent number: 5559101Abstract: This invention relates to .alpha. and .beta. L-ribofuranosyl nucleosides, processes for their preparation, pharmaceutical compositions containing them, and methods of using them to treat various diseases in mammals.Type: GrantFiled: October 24, 1994Date of Patent: September 24, 1996Assignees: Genencor International, Inc., Lipitek, Inc.Inventors: Alexander L. Weis, Kirupathevy Shanmuganathan, Charles T. Goodhue
-
Patent number: 5449691Abstract: A method for inducing the production of interleukin 2 in a warm blooded animal by administering an effective amount of a compound of the formula (I) ##STR1## wherein Y is ##STR2## NHSO.sub.2 or SO.sub.2 NH where R.sup.4 is H; Z is --O--, --NH--, --NR--, --S--, or other heteroatoms capable of hydrogen bonding with R.sup.4 to give a preferred conformation;R is alkyl;R.sup.1 is --NH.sub.2 or --NHCH.sub.3 ;R.sup.2 is H, alkyl, cycloalkyl, aralkyl, substituted or unsubstituted aryl, or a substituted or unsubstituted nitrogen heterocyclic group having 4 to 5 nuclear carbon atoms; andR.sup.3 is a lipophilic moiety.Type: GrantFiled: June 24, 1993Date of Patent: September 12, 1995Assignee: Sterling Winthrop Inc.Inventors: William N. Washburn, Lee H. Latimer, Barbara B. Lussier, Carl R. Illig, Alexander L. Weis
-
Patent number: 5310760Abstract: Certain 3,4-disubstituted anilines and pharmaceutically acceptable salts thereof are provided which mimic IL-1 activity by inducing IL-2 synthesis and subsequent IL-2 receptor expression. Specifically, the invention provides compounds of Formula I and acid addition salts thereof: ##STR1## wherein Y is ##STR2## NHSO.sub.2 or SO.sub.2 NH where R.sup.4 is H; Z is --O--, --NH--, --NR--, --S--, or other heteroatoms capable of hydrogen bonding with R.sup.4 to give a preferred conformation;R is alkyl;R.sup.1 is --NH.sub.2 or --NHCH.sub.3 ;R.sup.2 is H, alkyl, cycloalkyl, aralkyl, substituted or unsubstituted aryl, or a substituted or unsubstituted nitrogen heterocyclic group having 4 to 5 nuclear carbon atoms; andR.sup.3 is a lipophilic moiety.Type: GrantFiled: July 9, 1993Date of Patent: May 10, 1994Assignee: Sterling Winthrop Inc.Inventors: William N. Washburn, Lee H. Latimer, Barbara B. Lussier, Carl R. Illig, Alexander L. Weis
-
Patent number: 5245022Abstract: Compounds, compositions and methods for inhibiting gene expression are disclosed. The compounds comprise oligonucleotide sequences of from about 9 to about 200 bases having a diol at either or both termini. Preferred diols are polyalkyleneglycols, preferably polyethyleneglycols. Pharmaceutical compositions comprising the compounds and a physiologically acceptable carrier and methods of inhibiting gene expression in mammals comprising administering such compounds are also provided. Methods for inhibiting nuclease cleavage of compounds are also provided.Type: GrantFiled: August 3, 1990Date of Patent: September 14, 1993Assignee: Sterling Drug, Inc.Inventors: Alexander L. Weis, Fred T. Oakes, Frederick H. Hausheer, Paul F. Cavanaugh, Jr., Patricia S. Moskwa
-
Patent number: 5214134Abstract: A method of linking nucleosides with a siloxane bridge comprising reacting a 3'-silylated-5'-protected nucleoside with an unprotected nucleoside is disclosed. The silylated and unprotected nucleosides may be either monomeric nucleosides or the terminal nucleosides of an oligonucleotide or oligonucleotide analog. A method of synthesizing an oligonucleotide analog having siloxane internucleoside linkages is also disclosed. The method of synthesis comprises silylating a 5'-protected nucleoside with a bifunctional silylating reagent to form a 3'-silylated nucleoside, reacting the silylated nucleoside with an unprotected nucleoside in the presence of a base catalyst and repeating these steps to form an oligonucleotide analog. A modified solid phase synthesis method for preparing an oligonucleotide analog having siloxane internucleoside linkages is also disclosed.Type: GrantFiled: September 12, 1990Date of Patent: May 25, 1993Assignee: Sterling Winthrop Inc.Inventors: Alexander L. Weis, Ashis K. Saha, Frederick H. Hausheer
-
Patent number: 5075433Abstract: A novel 3-sulfatoglucuronic acid-containing compound is produced. A method for antibody removal from a liquid sample, and a method of treatment for antibody-related disorders is disclosed, along with a diagnostic kit.Type: GrantFiled: August 5, 1988Date of Patent: December 24, 1991Assignee: Eastman Kodak CompanyInventor: Alexander L. Weis
-
Patent number: 5068345Abstract: A oxazolidinone aldol adduct having the formula: ##STR1## wherein R is alkyl having 6 or more carbons or aryl; R.sup.1 is alkyl or aryl; R.sup.2 is alkyl, aryl or hydrogen; and X is a halogen atom or an azide. This aldol adduct is useful in a process for making 2-amino-1,3 diols.Type: GrantFiled: October 30, 1989Date of Patent: November 26, 1991Assignee: Eastman Kodak CompanyInventors: Carl R. Illig, Alexander L. Weis
-
Patent number: 5012000Abstract: A method for the preparation of chiral 2-amino-1,3-diols is disclosed. The method involves four steps including performance of an aldol condensation with a chiral oxazolidinone on an aldehyde, treating the aldol condensation product with an alkali metal azide, treating the product with a borohydride reagent and reducing the azide to an amine.Type: GrantFiled: October 30, 1989Date of Patent: April 30, 1991Assignee: Eastman Kodak CompanyInventors: Carl R. Illig, Alexander L. Weis